Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Kashif Iqbal

Internal Medicine Evansville, IN Medical Doctor

NPI 1942376074 CMS profile 360506

421 Chestnut St, Evansville, IN 47713

Open in the dashboard

General payments

$8,943

606 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Kashif Iqbal of Evansville, IN is reported in the CMS Open Payments database as having received $8,943 across 606 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 93rd percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,427 90
2024 General $1,687 101
2023 General $1,306 89
2022 General $692 43
2021 General $1,632 119
2020 General $1,081 76
2019 General $1,118 88

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kashif Iqbal
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Kashif Iqbal were reported at $1,427. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Kashif Iqbal Internal Medicine median Middle half National median
2019 $1,118 $159 $48–$570 $163
2020 $1,081 $119 $33–$402 $114
2021 $1,632 $135 $37–$521 $132
2022 $692 $141 $42–$496 $149
2023 $1,306 $149 $45–$519 $160
2024 $1,687 $154 $47–$537 $164
2025 $1,427 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novo Nordisk Inc $1,063 84 payments
  2. AbbVie, Inc. $1,008 81 payments
  3. GlaxoSmithKline, LLC. $971 60 payments
  4. Amgen Inc. $724 54 payments
  5. AstraZeneca Pharmaceuticals LP $598 25 payments
  6. Merck Sharp & Dohme Corporation $519 37 payments
  7. Corium, Inc. $340 23 payments
  8. Salix Pharmaceuticals, a division of Bausch Health US, LLC $314 19 payments
  9. Lilly USA, LLC $305 23 payments
  10. Boehringer Ingelheim Pharmaceuticals, Inc. $278 21 payments
  11. Other $2,823 179 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $8,795 591 payments
  2. Education $148 15 payments
Products named General payments · program years 2019–2025
  1. Ozempic $806 63 payments
  2. RYBELSUS $558 41 payments
  3. FARXIGA $539 20 payments
  4. UBRELVY $453 36 payments
  5. Repatha $450 35 payments
  6. SHINGRIX $417 24 payments
  7. TRELEGY ELLIPTA $375 26 payments
  8. BELSOMRA $362 25 payments
  9. Otezla $361 28 payments
  10. VRAYLAR $349 29 payments
  11. Other $8,769 566 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 134 drugs

Part D claims

8,150

Median for Internal Medicine: 777

Drug cost

$584,306

Median for Internal Medicine: $73,373

Branded share of claims

23.5%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Jardiance Empagliflozin Brand 127 $121,196
Eliquis Apixaban Brand 120 $108,839
Farxiga Dapagliflozin Propanediol Brand 56 $55,839
Ozempic Semaglutide Brand 44 $48,753
Mounjaro Tirzepatide Brand 27 $29,958
Rybelsus Semaglutide Brand 21 $22,192
Oxycontin Oxycodone Hcl Brand 12 $21,016
Xarelto Rivaroxaban Brand 15 $15,977
Spiriva Handihaler Tiotropium Bromide Brand 15 $15,153
Stiolto Respimat Tiotropium Br/Olodaterol Hcl Brand 25 $13,524

The 10 drugs with the highest cost, of 134 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 52 billing codes

Paid by Medicare

$100,443

Of which drugs: $15,701

Medicare patients

460

Average age 74

Services billed

2,092

227 women, 233 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 74%
Arthritis 45%
Chronic kidney disease 31%
Diabetes 27%
Atrial fibrillation 20%
Ischemic heart disease 19%
Depression 18%
Cancer 17%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Sarscv2 vac 30mcg trs-suc im 91320 Office 47 49 $7,389
Vaccine for influenza for injection into muscle 90662 Office 56 56 $4,582
Pcv20 vaccine im 90677 Office 11 11 $3,176

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 39 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
YUPELRI
  • Mylan Specialty L.P. $140
$140 — —
UBRELVY
  • AbbVie, Inc. $119
$119 — —
Azstarys
  • Corium, Inc. $107
$107 — —
REXULTI
  • Otsuka America Pharmaceutical, Inc. $106
$106 — —
TRELEGY ELLIPTA
  • GlaxoSmithKline, LLC. $102
$102 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 39 with Patron

Records

606 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Indiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record